Ketamine Therapy for Suicidal Ideation

What the Evidence Says About Ketamine for Suicidal Ideation

If you are in crisis right now, call or text 988 (Suicide & Crisis Lifeline) — a directory page is not the right tool for an emergency. For context on the medicine: the FDA has approved Spravato (esketamine), with an oral antidepressant, for "depressive symptoms in adults with major depressive disorder (MDD) with acute suicidal ideation or behavior."

The FDA label itself draws a careful line: "The effectiveness of SPRAVATO in preventing suicide or in reducing suicidal ideation or behavior has not been demonstrated." The approval covers rapid treatment of the depressive symptoms in that population — not suicide prevention as such. NIMH highlights why speed matters here, describing ketamine and esketamine as "medications known to rapidly reduce depressive symptoms in hours or days," and funds ongoing research on rapid-acting interventions for severe suicide risk.

FDA status: Spravato (esketamine) is FDA-approved for depressive symptoms in adults with MDD with acute suicidal ideation or behavior — with an important limitation noted below.

Sources:

• FDA prescribing information for Spravato (esketamine)
• NIMH — Rapid-Acting Interventions for Severe Suicide Risk (2021)

Related Reading

• Does Spravato Work for Depression?
• Ketamine Side Effects: Is Ketamine Therapy Safe?